High rates of antimicrobial co-resistance among Enterobacteriaceae: Comparative analysis between clinical isolates resistant and susceptible to third-generation cephalosporins

Revista Espanola de Quimioterapia

Volumn 20, Issue 2, 2007, Pages 216-221

  Goyanes, M J ^a   Cercenado, Emilia ^a   Insa, R ^a   Morente, A ^a   Alcala L ^a   Bouza, E ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Beta lactamases; Co resistance; Enterobacteriaceae resistance; Third generation cephalosporins

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CITROBACTER FREUNDII; COMPARATIVE STUDY; CONTROLLED STUDY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MORGANELLA MORGANII; PROTEUS MIRABILIS; SALMONELLA; SERRATIA MARCESCENS; SPECIES COMPARISON;

ANTI-BACTERIAL AGENTS; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; SPAIN;

EID: 34548272661     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Álvarez, M., Tran, J.H., Chow, N., Jacoby, G.A. Epidemiology of conjugative plasmid-mediated AmpC beta-lactamases in the United States. Antimicrob Agents Chemother 2004; 48: 533-537.
2. Bradford, P.A. Extended-spectrum β-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-951.
3. Paterson, D.L. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am J Infect Contr 2006; 34: S20-S28.
4. Paterson, D.L., Bonomo, R.A. Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev 2005; 18: 657-686.
5. Philippon, A., Arlet, G., Jacoby G.A. Plasmid-determined AmpC-type β-lactamases. Antimicrob Agents Chemother 2002; 46: 1-11.
6. Zanetti,G., Bally, F., Greub, G. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: A multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003; 47: 3442-3447.
7. Bouza, E., Cercenado, E. Klebsiella and Enterobacter: Antibiotic resistance and treatment implications. Semin Respir Infect 2002; 17: 215-230.
8. Chow, J.W., Fine, M.J., Shlaes, D.M. et al. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585-590.
9. Cosgrove, S.E., Kaye, K.S., Eliopoulos, G.M., Carmeli, Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002; 162: 185-190.
10. Kaye, K.S., Harris, S.A., Eliopoulos, G.M., Carmeli, Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobatter spp. Antimicrob Agents Chemother 2001; 45: 2628-26.30.
11. Helfand, M.S., Bonomo, R.A. Current challenges in antimicrobial chemotherapy: The impact of extended-spectrum β-lactamases and metallo-lactamases on the treatment of resistant Gram-negative pathogens. Curr Opin Pharmacol 2005; 5: 452-458.
12. Schwaber, M.J., Navon-Venezia, S., Carmeli, Y. High level of antimicrobial coresistance among extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2005; 49: 2137-2139.
13. Brise, S., Milatovic, D., Fluit, A.C., Verhoef, J., Schitz, F.J. Epidemiology of quinolone resistance of Klebsiella pneumoniae and Klebsiella oxytoca in Europe. Eur J Clin Microbiol Infect Dis 2000; 19: 64-68.
14. Jacoby, G.A., Chow, N., Waites, K.B. Prevalence of plasmid-mediated quinolone resistance. Antimicrob Agents Chemother 2003; 47: 559-562.
15. Mammeri, H., Van de Loo, M., Poirel, L., Martínez-Martínez, L., Nordmann, P. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob Agents Chemother 2005; 49: 71-76.
16. Paterson, D.L., Mulazimoglu, L., Casellas, J.M. et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30: 473-478.
17. Wang, M., Sahm, D.F., Jacoby, G.A., Hooper, D.C. Emerging mediated quinolone resistance associated with the qnr gene in Klebsiella plasmid-pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother 2004; 48: 1295-1299.
18. Brun-Buisson, C., Legrand, P., Philippon, A. et al. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet 1987; ii: 302-306.
19. Livermore, D.M., Yuan, M. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother 1996; 38: 409-424.
20. Naumovski, L., Quinn, J.P., Miyashiro, D. et al. Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 1992; 36: 1991-1996.
21. Urban, C., Meyer, K.S., Mariano, N. et al. Identification of TEM-26 beta-lactamase responsible for a major outbreak of ceftazidime-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 1994; 38: 392-395.
22. CLSI. Performance standards for antimicrobial susceptibility testing 16th informational supplement. Approved standard M100-S16, Clinical and Laboratory Standards Institute, Wayne, Pa 2006.
23. De Cueto, M., López, L., Hernández, J.R., Morillo, C., Pascual, A. In vitro activity of fosfomycin against extended-spectrum-beta- lactamase-producing Escherichia coli and Klebsiella pneumoniae: Comparison of susceptibility testing procedures. Antimicrob Agents Chemother 2006; 50: 368-370.
24. Brown, D.F., Andrews, J., King, A., MacGowan, A.P. Detection of extended-spectrum beta-lactamases with E-test and double-disc potentiation methods. J Antimicrob Chemother 2000; 46: 327-328.
25. Jarlier, V., Nicolas, M.H., Fournier, G., Philippon, A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: Hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-878.
26. Spanu, T., Luzzaro, F., Perilli, M. et al., The Italian ESBL Study Group. Occurrence of extended-spectrum β-lactamases in members of the family Enterobacteriaceae in Italy: Implications for resistance to β-laclams and other antimicrobial drugs. Antimicrob Agents Chemother 2002; 46: 196-202.
27. Du, B., Long, Y., Liu, H. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: Risk factors and clinical outcome. Intensive Care Med 2002; 28: 1718-1723.
28. Jett, B.D., Ritchie, D.J., Reichley, R., Bailey, T.C., Sahm, D.F. In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins. Antimicrob Agents Chemother 1995; 39: 1187-1190.
29. Paterson, D.L. Ko, W.C., Von Gottberg, A. Antibiotic therapy for Klebsiella pneumoniae bacteremia: Implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39: 31-37.
30. Thomson, K.S. Moland, E.S. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001; 45: 3548-3554.
31. Rodríguez-Baño, J., Navarro, M.D., Romero, L. et al. Epidemiology and clinical features of infectious caused by extended-spectrum beta-lactamases producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-1094.
32. Safdar, N., Maki, D.G. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136: 834-844.
33. Andreu, A., Alos, J.I., Gobernado, M. et al. Etiology and antimicrobial susceptibility among uropathogens causing community acquired lower urinary tract infections: A nationwide surveillance study. Enferm Infecc Microbiol Clin 2005; 23: 1-3.
34. Ungheri, D., Albini, E., Belluco, G. In vitro susceptibility of quinolone resistant clinical isolates of Escherichia coli to fosfomycin trometamol. J Chemother 2002; 14: 237-240.